GILEAD SCIENCES INC (NASDAQ: GILD)

GILEAD SCIENCES INC

NASDAQ: GILD (Gilead Sciences, Inc.)

Kemas kini terakhir: 15 May, 2:22PM

99.81

1.43 (1.45%)

Tambah ke senarai pantauan

Penutupan Terdahulu	98.38
Buka	99.53
Jumlah Dagangan	5,440,691
Purata Dagangan (3B)	9,895,855
Modal Pasaran	124,263,440,384

Harga / Pendapatan (P/E TTM)	20.97
Harga / Pendapatan (P/E Ke hadapan)	14.20
Harga / Jualan (P/S)	4.92
Harga / Buku (P/B)	7.30

Julat 52 Minggu	62.07 (-37%) — 119.96 (20%)
Tarikh Pendapatan	6 Aug 2025 - 11 Aug 2025
Hasil Dividen (DY TTM)	3.13%

Arah Aliran Pasaran

		Jangka Pendek	Jangka Sederhana
Industri	Drug Manufacturers - General (US)	Menurun	Bercampur
	Drug Manufacturers - General (Global)	Menurun	Bercampur
Stok	Gilead Sciences, Inc.	Menaik	Menaik

AISkor Stockmoo

1.7

Konsensus Penganalisis	4.0
Aktiviti Orang Dalam	-1.5
Volatiliti Harga	2.0
Purata Bergerak Teknikal	0.0
Osilator Teknikal	4.0
Purata	1.70

Saham Serupa

Stok	Modal Pasaran	DY	P/E (TTM)	P/B
GILD	124 B	3.13%	20.97	7.30
AMGN	157 B	3.17%	26.31	25.15
AZN	226 B	2.13%	29.27	6.19
SNY	122 B	4.43%	17.53	1.46
GRFS	6 B	-	28.00	0.910
BIIB	17 B	-	11.68	1.14

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Sektor	Healthcare
Industri	Drug Manufacturers - General
Gaya Pelaburan	Large Value
% Dimiliki oleh Orang Dalam	0.12%
% Dimiliki oleh Institusi	89.68%

Julat 52 Minggu	62.07 (-37%) — 119.96 (20%)
Julat Harga Sasaran	125.00 (25%) — 135.00 (35%)
Tinggi	135.00 (Morgan Stanley, 35.26%)	Beli
Median	127.50 (27.74%)
Rendah	125.00 (Oppenheimer, 25.24%)	Beli
	125.00 (Cantor Fitzgerald, 25.24%)	Beli
Purata	128.75 (29.00%)
Jumlah	4 Beli
Harga Purata @ Panggilan	105.75

Syarikat	Tarikh	Harga Sasaran	Panggilan	Harga @ Panggilan
Morgan Stanley	25 Apr 2025	135.00 (35.26%)	Beli	103.17
Oppenheimer	25 Apr 2025	125.00 (25.24%)	Beli	103.17
Cantor Fitzgerald	22 Apr 2025	125.00 (25.24%)	Beli	105.51
JP Morgan	27 Mar 2025	130.00 (30.25%)	Beli	111.16

Tiada data dalam julat masa ini.

Tarikh	Jenis	Butiran
01 Jun 2025	Pengumuman	Kite Presents New Real-World Data Supporting Use of Potentially Curative Yescarta® in Outpatient Care Setting for Patients with Relapsed/Refractory Large B-Cell Lymphoma at ASCO 2025
31 May 2025	Pengumuman	Trodelvy® Plus Keytruda® Reduces Risk of Disease Progression or Death by 35% Versus Keytruda and Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer
23 May 2025	Pengumuman	ASCENT-03: Trodelvy® Demonstrates Highly Statistically Significant & Clinically Meaningful Improvement in Progression Free Survival in Patients With First-line Metastatic Triple-Negative Breast Cancer Who Are Not Candidates for Checkpoint Inhibitors
15 May 2025	Pengumuman	Gilead and Kite Announce Presentation of Transformative Data in 1L Metastatic Triple-Negative Breast Cancer, Updated Results in Multiple Myeloma and Early Data From Novel Investigational CAR T-Cell Therapy Targeting Brain Cancer at 2025 ASCO and EHA
12 May 2025	CNBC	Trump's plan to slash drug prices may struggle to get off the ground – here's what to know
07 May 2025	Pengumuman	Final Data From the Phase 3 MYR301 Study Demonstrated Longer Treatment With Bulevirtide Was Associated With Sustaining Undetectability After Stopping Treatment
07 May 2025	Pengumuman	Gilead’s Livdelzi® (Seladelpar) Demonstrated Consistent Efficacy and Safety Regardless of Prior Treatment History in New Data Presented at EASL 2025
29 Apr 2025	Pengumuman	Gilead to Present Latest Advancements Across Primary Biliary Cholangitis and Viral Hepatitis
29 Apr 2025	Pengumuman	Gilead Sciences to Present at Upcoming Investor Conferences
28 Apr 2025	Pengumuman	Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of Development
24 Apr 2025	Pengumuman	Gilead Sciences Announces First Quarter 2025 Financial Results
24 Apr 2025	CNBC	Corporate America shelled out millions for Trump's inauguration. Now he's upending many of their businesses
21 Apr 2025	Pengumuman	Trodelvy® Plus Keytruda® Demonstrates a Statistically Significant and Clinically Meaningful Improvement in Progression Free Survival in Patients With Previously Untreated PD-L1+ Metastatic Triple-Negative Breast Cancer
10 Apr 2025	Pengumuman	Gilead Sciences to Release First Quarter 2025 Financial Results on Thursday, April 24, 2025
Papar semua

Hasil Dividen (DY TTM)	3.13%
Purata Hasil Dividen 5T	3.80%
Nisbah Pembayaran	65.13%
Jangkaan Pembayaran Dividen Seterusnya	Sep 2025

Tarikh EX	Tarikh Pengumuman	Tarikh Pembayaran	Perincian
13 Jun 2025	22 Apr 2025	27 Jun 2025	0.79 Tunai
14 Mar 2025	05 Feb 2025	28 Mar 2025	0.79 Tunai
13 Dec 2024	30 Oct 2024	30 Dec 2024	0.77 Tunai
13 Sep 2024	30 Jul 2024	27 Sep 2024	0.77 Tunai
14 Jun 2024	23 Apr 2024	27 Jun 2024	0.77 Tunai
14 Mar 2024	01 Feb 2024	28 Mar 2024	0.77 Tunai
14 Dec 2023	01 Nov 2023	28 Dec 2023	0.75 Tunai
14 Sep 2023	25 Jul 2023	28 Sep 2023	0.75 Tunai
14 Jun 2023	25 Apr 2023	29 Jun 2023	0.75 Tunai
14 Mar 2023	25 Jan 2023	30 Mar 2023	0.75 Tunai
14 Dec 2022	25 Oct 2022	29 Dec 2022	0.73 Tunai
14 Sep 2022	25 Jul 2022	29 Sep 2022	0.73 Tunai
14 Jun 2022	27 Apr 2022	29 Jun 2022	0.73 Tunai
14 Mar 2022	28 Jan 2022	30 Mar 2022	0.73 Tunai
14 Dec 2021	26 Oct 2021	30 Dec 2021	0.71 Tunai
14 Sep 2021	26 Jul 2021	29 Sep 2021	0.71 Tunai
14 Jun 2021	27 Apr 2021	29 Jun 2021	0.71 Tunai
12 Mar 2021	02 Feb 2021	30 Mar 2021	0.71 Tunai
14 Dec 2020	26 Oct 2020	30 Dec 2020	0.68 Tunai
14 Sep 2020	29 Jul 2020	29 Sep 2020	0.68 Tunai
11 Jun 2020	29 Apr 2020	29 Jun 2020	0.68 Tunai
12 Mar 2020	03 Feb 2020	30 Mar 2020	0.68 Tunai
12 Dec 2019	23 Oct 2019	30 Dec 2019	0.63 Tunai
12 Sep 2019	29 Jul 2019	27 Sep 2019	0.63 Tunai
13 Jun 2019	01 May 2019	27 Jun 2019	0.63 Tunai
14 Mar 2019	01 Feb 2019	28 Mar 2019	0.63 Tunai
13 Dec 2018	24 Oct 2018	28 Dec 2018	0.57 Tunai
13 Sep 2018	24 Jul 2018	27 Sep 2018	0.57 Tunai
14 Jun 2018	30 Apr 2018	28 Jun 2018	0.57 Tunai
15 Mar 2018	05 Feb 2018	29 Mar 2018	0.57 Tunai
14 Dec 2017	25 Oct 2017	28 Dec 2017	0.52 Tunai
14 Sep 2017	25 Jul 2017	28 Sep 2017	0.52 Tunai
14 Jun 2017	01 May 2017	29 Jun 2017	0.52 Tunai
14 Mar 2017	06 Feb 2017	30 Mar 2017	0.52 Tunai
13 Dec 2016	31 Oct 2016	29 Dec 2016	0.47 Tunai
14 Sep 2016	22 Jul 2016	29 Sep 2016	0.47 Tunai
14 Jun 2016	27 Apr 2016	29 Jun 2016	0.47 Tunai
14 Mar 2016	02 Feb 2016	30 Mar 2016	0.43 Tunai
14 Dec 2015	26 Oct 2015	30 Dec 2015	0.43 Tunai
14 Sep 2015	23 Jul 2015	29 Sep 2015	0.43 Tunai
12 Jun 2015	24 Apr 2015	29 Jun 2015	0.43 Tunai
Papar semua

Hasil Dividen Tahunan

Tahun	Dividen Tahunan ($)	Kekerapan/Tahun	Hasil %
2025	1.58	2	1.58
2024	3.08	4	3.33
2023	3.00	4	3.70
2022	2.92	4	3.40
2021	2.84	4	3.91
2020	2.72	4	4.67
2019	2.52	4	3.88
2018	2.28	4	3.65
2017	2.08	4	2.90
2016	1.84	4	2.57
2015	1.29	3	1.28
Papar semua

Portfolio

Log masuk untuk menambahkan ke senarai pantauan

AI Templat

Peringatan harga anda

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Log masuk untuk menambahkan ke senarai pantauan

Keuntungan Nyata	-
Keuntungan Tidak Nyata	-
Dividen Diterima 2025	-
Jumlah Untung	-
Pulangan Purata	-
Kuantiti (Beli)	-
Purata Harga (Beli)	-
Kuantiti (Jual)	-
Purata Harga (Jual)	-

Log masuk untuk menambahkan ke senarai pantauan

Tiada saham yang memenuhi kriteria anda

Margin Keuntungan	20.76%
Margin Operasi (TTM)	38.49%
EPS Cair (TTM)	4.76
Pertumbuhan Hasil Suku Tahunan (YOY)	-0.30%
Pertumbuhan Pendapatan Suku Tahunan (YOY)	24.80%

Jumlah Hutang/Ekuiti (D/E MRQ)	130.79%
Nisbah Semasa (MRQ)	1.37
Aliran Tunai Operasi (OCF TTM)	10.37 B
Aliran Tunai Bebas Leveraj (LFCF TTM)	9.99 B

Pulangan Atas Aset (ROA TTM)	12.14%
Pulangan Atas Ekuiti (ROE TTM)	32.65%

Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)